But these days, immunotherapies like “pembrolizumab” and “PD-L1 monoclonal antibody”—targeted medicines for various subtypes of breast cancer—have acquired popularity as a means of treating TNBC, and their significance cannot be ignored. The gene discussed is CD274; the disease is breast carcinoma.